New Data to be Presented from EFTISARC-NEO Phase II Evaluating Novel Triple Combination including Immutep’s Efti in Soft Tissue Sarcoma
Results from triple combination of efti, radiotherapy and KEYTRUDA® (pembrolizumab) to be presented at the Connective Tissue Oncology Society ...
PharmiWeb8d
Transgene and BioInvent’s Oncolytic Virus BT-001 S…
Preliminary data presented at ESMO 2024 demonstrate that BT-001 induces tumor regression in patients who failed previous anti-PD(L)-1 treatmentIn a patient with a heavily pretreated leiomyosarcoma, BT ...
Pharmabiz8d
Cytovation to present safety and efficacy data from CICILIA phase I/IIa clinical trial evaluating CY-101 in solid tumors
Cytovation to present safety and efficacy data from CICILIA phase I/IIa clinical trial evaluating CY-101 in solid tumors: Bergen, Norway Monday, September 16, 2024, 18:00 Hrs [IST ...
PDS Biotech Announces Updated Results from VERSATILE-002 Phase 2 Clinical Trial Presented at ESMO 2024
Median Overall Survival remains at 30 months; Objective Response Rate of 36% and Disease Control Rate of 77% 11/53 (21%) of patients experienced 90-100% tumor shrinkage VERSATILE-003 Phase 3 clinical ...
Business Insider8d
Immutep’s Efti in Combination with MSD’s KEYTRUDA® Leads to Positive Efficacy with Favourable Safety in First Line Head and Neck Cancer
We are excited to see efti in combination with KEYTRUDA now driving a 1.9-fold increase in responses ... The ESMO Proferred ...
Le Lézard13d
Pfizer Highlights Diverse Oncology Portfolio and Combination Approaches at ESMO 2024
PADCEV + KEYTRUDA**: additional analysis from the pivotal EV-302 ... PF-07104091 in HR+ HER2- metastatic breast cancer and advanced solid tumors Yap et al Poster Presentation (Abstract 413P) Monday, ...
TMCnet15d
PDS Biotech to Present Updated VERSATILE-002 Data at ESMO Congress 2024
PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers and the ...
AOL15d
Summit Therapeutics' Lung Cancer Candidate Surpasses Merck's Multi-Billion Dollar Keytruda, Cuts Risk Of Disease Or Death By Half
The trial evaluated monotherapy ivonescimab against monotherapy Merck & Co Inc’s (NYSE:MRK) Keytruda (pembrolizumab) in patients with locally advanced or metastatic non-small cell lung cancer ...
clinicaltrialsarena16d
Summit’s checkpoint inhibitor trumps Keytruda in lung cancer trial
Summit Therapeutics’s drug ivonescimab reduced the risk of lung cancer progression or death by nearly half, compared to MSD’s blockbuster drug Keytruda (pembrolizumab) in Phase III data showcased on 8 ...
Nasdaq18d
Pharma Stock Roundup: EU Nod for Expanded Use of MRK's Keytruda & More
Merck’s Keytruda Combo for Urothelial Carcinoma Gets EU Approval: The European Commission granted approval to Merck’s Keytruda in combination with Astellas/Pfizer’s antibody-drug conjugate ...
The Hill21d
Philadelphia Eagles: Posters claiming team endorsed Harris are ‘counterfeit political ads’
The Philadelphia Eagles said posters popping up in Philadelphia that show the team has endorsed Vice President Harris are “counterfeit political ads.” The posters appeared at bus stop shelters ...